Analysis Of Income And Expense [Abstract]

Egetis Therapeutics - Filing #690710

Concept	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue	—	—	226,000,000 SEK	—	—	—	—	—	382,000,000 SEK	—
Material income and expense [abstract]
Other operating income (expense)	—	—	11,000,000 SEK	—	—	—	—	—	6,000,000 SEK	—
Revenue and other operating income	—	—	226,000,000 SEK	—	—	—	—	—	385,000,000 SEK	—
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Employee benefits expense	—	—	520,000,000 SEK	—	—	—	—	—	301,000,000 SEK	—
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss	—	—	27,000,000 SEK	—	—	—	—	—	25,000,000 SEK	—
Other expenses, by nature	—	—	223,000,000 SEK	—	—	—	—	—	145,000,000 SEK	—
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income	– SEK	– SEK	1,938,000,000 SEK	1,938,000,000 SEK	– SEK	– SEK	– SEK	– SEK	1,045,000,000 SEK	1,045,000,000 SEK